No profile data available.
Compugen Ltd. (CGEN) is a healthcare company in the additional cancer treatment drugs industry, based in Holon, Israel, with about 75 full-time employees.
It reported revenue of $72.76 million for fiscal year 2025, up 161.1% from fiscal year 2024, and net income of $35.34 million. United Kingdom was its largest region in fiscal year 2025, with 89% of revenue. Its market capitalization was $201.76 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.
Compugen reported $72.76 million in revenue for fiscal year 2025, up 161.1% from $27.86 million in fiscal year 2024.
United Kingdom: 89% of revenue by region in fiscal year 2025, followed by United States (11%).
$201.76 million as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Pyxis Oncology, Inc. (PYXS), MacroGenics, Inc. (MGNX), Sutro Biopharma, Inc. (STRO), Whitehawk Therapeutics, Inc. (WHWK).